Translate Our Affiliations
Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.
Kimberly Stegmaier, MD
- Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute
- Ted Williams Chair, Dana-Farber Cancer Institute
- Associate Chief, Division of Hematology/Oncology, Boston Children’s Hospital
- Physician
- Professor of Pediatrics, Harvard Medical School
- Institute Member, Broad Institute
Appointment Phone
- 617-632-3270 (established patients)
- 888-733-4662 (new patients)
Fax
- 617-632-4850
General
Treatment Centers
Discipline
Clinical Interests
Cancer genomics, Chemical screening, Ewing sarcoma, Hematologic malignancies, Neuroblastoma
Location
Background
Board Certifications
Fellowship
Residency
Medical School
Biography
Kimberly Stegmaier, MD, is Chair of the Department of Pediatric Oncology, Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology at Boston Children’s Hospital; Professor of Pediatrics at Harvard Medical School; and currently the Ted Williams Chair at Dana-Farber Cancer Institute. She has been a faculty member at Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School since 2002 and an independent investigator since 2006. Dr. Stegmaier is dedicated to the goal of precision pediatric oncology medicine, pioneering the development and application of innovative genomic approaches to identify new therapies for childhood cancer. She has focused her efforts on acute leukemias and pediatric solid tumors of childhood — particularly those driven by fusion oncoproteins. Her lab has discovered novel technologies, concepts, and targets with translational impact.
Dr. Stegmaier received her undergraduate degree from Duke University, and medical degree from Harvard Medical School, and completed training in Pediatrics and Pediatric Hematology/Oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute.
Research
Principal Investigator
My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.